EUPRAXIA PHARMACEUTICALS INC.

Eupraxia Pharmaceuticals Inc. announced that abstracts related to its ongoing Phase 1b/2 RESOLVE trial of EP-104GI for eosinophilic esophagitis (EoE) have been accepted for presentation at the American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) medical conferences. The presentations will cover data showing improvements in dysphagia and histopathological features persisting up to 52 weeks. The company also noted that interim data from the Phase 2b portion of the RESOLVE trial is expected in December 2026. Eupraxia is leveraging its proprietary Diffusphere™ technology for localized drug delivery.

Eupraxia Pharmaceuticals announced positive symptom response data from a new analysis of its ongoing Phase 1b/2a RESOLVE trial for EP-104GI in Eosinophilic Esophagitis (EoE) patients. The analysis showed significant reductions in both odynophagia (painful swallowing) and dysphagia (difficulty swallowing) severity, with improvements sustained up to 52 weeks. EP-104GI continues to be well tolerated, with no treatment-emergent or procedure-related Serious Adverse Events reported across over 130 patients.

Eupraxia Pharmaceuticals reported a net loss of $(14.49) million for Q2 2026, an increase from $(8.75) million in Q2 2025, though loss per share improved to $(0.23). The company highlighted positive new data for its EP-104GI candidate from the RESOLVE trial, demonstrating improvement in fibrosis and inflammation. Eupraxia also strengthened its leadership team and confirmed it is well-funded to advance its Phase 2b Eosinophilic Esophagitis (EoE) trial, with interim data anticipated in Q4 2026.

Eupraxia Pharmaceuticals announced its second quarter 2026 financial results, reporting a net loss of $14.5 million, an increase from $8.7 million in the prior year, primarily due to increased R&D costs. The company maintains a strong financial position with $133.6 million in cash and short-term investments, projected to fund operations into the second half of 2028. Operationally, Eupraxia presented positive data for EP-104GI at Digestive Disease Week, demonstrating improvement in fibrosis and inflammation in Eosinophilic Esophagitis (EoE) patients, with 66% achieving clinical remission in symptoms at week 36. The executive team and Board were also strengthened with key appointments to bolster late-stage drug development and global commercialization capabilities.

Eupraxia Pharmaceuticals Inc. has filed a preliminary short form base shelf prospectus, enabling the company to offer various securities with an aggregate offering price of up to US$300,000,000. This registration covers common shares, preferred shares, debt securities, warrants, subscription receipts, and units, which can be offered from time to time over a 25-month period. The securities may be offered by the company or its securityholders and can also be used as consideration for acquisitions.

Eupraxia Pharmaceuticals announced updates to its executive leadership and operating structure on July 13, 2026, to prepare for its next stage of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, and Dr. Alex Therien took the helm of Research & Development. The company also transitioned its operations from Victoria to Vancouver and Seattle, with key executive positions, including the CEO, now based in Seattle. Amanda Malone stepped down from her role as Chief Scientific and Operating Officer.

Eupraxia Pharmaceuticals announced significant changes to its executive leadership team to support its next phase of clinical and commercial development. Dr. Jeff Millard joined as Executive Vice President, Technical Operations, bringing extensive experience in CMC and regulatory strategy. Dr. Alex Therien will now lead Research & Development as Executive Vice President, R&D. Additionally, Amanda Malone stepped down from her role, and the company is transitioning its operations to Vancouver and Seattle, with key executives based in Seattle.

Eupraxia Pharmaceuticals Inc. announced the appointment of three new industry leaders, Robert Bazemore, Amy Pott, and Dr. Helen Thackray, to its Board of Directors. These appointments are expected to strengthen the company's expertise in late-stage drug development, commercial strategy, and global product launches, particularly as it advances its EP-104GI program and expands its pipeline. The company also acknowledged the departure of long-serving directors Paul Geyer and Michael Wilmink.

Eupraxia Pharmaceuticals announced the results of its Annual General Meeting of Shareholders held on June 18, 2026. Shareholders approved the election of all seven management-proposed nominees to the Board of Directors. Additionally, KPMG LLP was re-appointed as the company's auditor for the upcoming year, and shareholders authorized the Board to fix the auditors' remuneration. All items of business presented at the meeting were passed with strong shareholder support.

Eupraxia Pharmaceuticals Inc. announced the results of its Annual General Meeting held on June 18, 2026. All seven nominees proposed by management for election to the Company's board of directors were successfully elected. Additionally, shareholders re-appointed KPMG LLP as the auditor for the upcoming year and authorized the Board to determine their remuneration. All items of business presented at the meeting were passed by the shareholders.